Skip to Content

NewLink Genetics Corporation

Company NameNewLink Genetics Corporation
Stock SymbolNLNK

The Firm announces an investigation on behalf of investors of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

NewLink, a biopharmaceutical company, purportedly focuses on discovering, developing and commercializing immunotherapeutic products to enhance treatment options for patients with cancer.

On May 9, 2016, post-market, NewLink disclosed that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L failed to satisfy the main purpose of a late-stage study. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's phase III trial, compared to median survival of 30.4 months for patients treated with conventional therapy. And, these trial results demonstrate that patients might have actually been hurt by NewLink's treatment.

On this news, shares of NewLink fell $5.05 per share, or over 30%, to close on May 10, 2016 at $11.45 per share.

If you purchased NewLink securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to

Submit Your Information

If you suffered a loss on your NewLink Genetics Corporation investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd